Tan et al. found that in hepatocellular carcinoma, HCV core protein reduces sensitivity to cisplatin by downregulating RUNX3 via inhibition of NR4A1 and upregulation of Smad7 [183]. Here, RUNX3 is linked to hepatocellular carcinoma.